Reader On-Costs, page-24

you are also making same mistake the board did at last CR and missing any valuation on the battery tech which will hopefully eclipse covid sales in time you then are also missing all the blue sky - additional tests- troponin, sepsis, covid/flu multiplex, diabetes, drug, concussion, etc etc etc
you also not adding in anything for all the other blue sky future potential applications for the tech. I have been in the story for around a decade and so far they have managed to create one of the worlds leading covid, flu and sepsis tests, along with some world leading silicon anode battery tech- this was done with a limited team of around 20 people and average of approx $4- $6M of capital a year to play with. Imagine what the next tech applications begin to look like with 100 people and $300M of capital to play with. Things will happen much quicker in multiple fields. Yeah I am a bit bullish on Anteo prospects but with all the worlds and National media and government attention on rapid testing and green energy and anteo having world leading proven tech in both places you would be silly not to be. The buzz word for the 2020s I reckon will be nanotechnology by the time the decade is over. This is still my favourite screensaver all these years later…